Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Expected CMS Payment Demos Could Shift Locus Of Part D Drug Purchasing

Executive Summary

Future demonstration projects by the Center for Medicare and Medicaid Innovation are likely to experiment with shifting drug purchasing decisions from Medicare Part D plans to health care providers such as hospitals, large health clinics or multi-specialty physician practices

You may also be interested in...



One To Watch: CMS Innovation Center Gets Chief, High-Priority Focus

The new payment innovation center at the Centers for Medicare and Medicaid Services is shaping up as a high-priority program for the agency, as demonstrated by the recent appointment of former Geisinger executive Richard Gilfillan to head the unit.

One To Watch: CMS Innovation Center Gets Chief, High-Priority Focus

The new payment innovation center at the Centers for Medicare and Medicaid Services is shaping up as a high-priority program for the agency, as demonstrated by the recent appointment of former Geisinger executive Richard Gilfillan to head the unit.

Berwick’s Call To Action: CMS Needs Industry Partners With “Authentic” Aims

The Centers for Medicare and Medicaid Services is seeking stakeholder collaboration to implement health care reforms but will only work with partners dedicated to true change, CMS Administrator Donald Berwick asserted at the America’s Health Insurance Plans Medicare conference in Washington, D.C., Sept. 13.

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS052182

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel